{"id":"js002","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JS002 binds to programmed death receptor 1 (PD-1) on T cells, preventing engagement with PD-L1 and PD-L2 expressed on tumor cells and immune cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.","oneSentence":"JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:04.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Hepatocellular carcinoma"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT05621070","phase":"PHASE3","title":"Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-03","conditions":"Primary Hypercholesterolaemia and Mixed Dyslipidemia","enrollment":582},{"nctId":"NCT05859529","phase":"PHASE1","title":"A Pharmacokinetic Study of JS002 in Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-05-30","conditions":"Health Volunteer","enrollment":318},{"nctId":"NCT04515927","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of JS002 in HoFH Patients","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-08-17","conditions":"Hyperlipemia","enrollment":31},{"nctId":"NCT05128539","phase":"PHASE1","title":"A Study Explore JS001+JS002 in Patients With Advanced Cancer","status":"TERMINATED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Advanced Cancer","enrollment":9},{"nctId":"NCT05325203","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-12-31","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":135},{"nctId":"NCT04781114","phase":"PHASE3","title":"The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-12-23","conditions":"Hyperlipemia","enrollment":806},{"nctId":"NCT05532800","phase":"PHASE3","title":"The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-28","conditions":"Hyperlipemia","enrollment":255},{"nctId":"NCT04469673","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-05-23","conditions":"Hyperlipemia","enrollment":90},{"nctId":"NCT04197817","phase":"PHASE1","title":"A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-12-11","conditions":"Hypercholesterolemia","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant humanized Anti- PCSK9 monoclonal antibody"],"phase":"phase_3","status":"active","brandName":"JS002","genericName":"JS002","companyName":"Shanghai Junshi Bioscience Co., Ltd.","companyId":"shanghai-junshi-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}